Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

Inclusion Criteria:

* Ages and sexes eligible: at least 22 years, male and female
* Candidates with known infected TKA
* Life expectancy of at least 1 year
* Patient is willing to provide informed consent, is geographically stable and able to comply with the required follow up visits, testing schedule and medication regimen
* Adequate soft tissue coverage
* Signed institutional review board approved informed consent

Exclusion Criteria:

* Severe renal impairment with eGFR \<50 ml/min/1.73 m2, or being treated with dialysis

  * Known hypersensitivity to aminoglycoside antibiotics, or calcium hydroxyapatite
  * Pre-existing calcium metabolism disorder
  * Uncontrolled diabetes mellitus (hemoglobin A1c levels \> 8)
  * A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroid parathyroid hormone disorder, Ehler- Danlos syndrome, osteogenesis imperfecta)
  * Neuromuscular disorders such as myasthenia gravis
  * Untreated malignant neoplasm(s), or currently undergoing radiation chemotherapy
  * Inadequate neurovascular status in the involved limb that may jeopardize healing
  * HIV
  * Pregnancy
  * Adult patients requiring a legal guardian to sign informed consent form